DOCSLIB.ORG

The Morbid Anatomy of the Human Genome: Chromosomal Location of Mutations Causing Disease

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Morbid Anatomy of the Human Genome: Chromosomal Location of Mutations Causing Disease J Med Genet 1993; 30: 1-26 I REVIEW ARTICLE The morbid anatomy of the human genome: chromosomal location of mutations causing disease Victor A McKusick, Joanna S Amberger Abstract Title - name of gene locus. Information is given in tabular form de- MIM# - This is the number in McKusick's rived from a synopsis of the human gene Mendelian Inheritance in Man, 10th ed (1992) map which has been updated continu- and its continuously updated online version ously since 1973 as part of Mendelian OMIM. (For historical reasons, the number Inheritance in Man Johns Hopkins may sometimes indicate location ofthe entry in University Press, 10th ed, 1992) and of the 'dominant catalogue' because the wildtype OMIM (Online Mendelian Inheritance in gene was characterised and mapped before the Man, available generally since 1987). The recessive disorder resulting from mutation at part of the synopsis reproduced here that site. The practice is to create only one consists of chromosome by chromosome entry in OMIM for each gene locus.) gene lists of loci for which there are asso- ciated disorders (table 1), a pictorial rep- resentation of this information (fig la-d), and an index of disorders for which the Method of mapping causative mutations have been mapped A = in situ DNA-RNA or DNA-DNA anneal- (table 2). ing ('hybridisation'), for example, ribosomal In table 1, information on genes that RNA genes to acrocentric chromosomes; have been located to specific chromoso- kappa light chain genes to chromosome 2. mal positions and are also the site of AAS = deductions from the amino acid disease producing mutations is arranged sequence of proteins, for example, linkage by chromosome, starting with chromo- of delta and beta globin loci from study of some 1 and with the end of the short arm hemoglobin Lepore. of the chromosome in each case. C = chromosome mediated gene transfer In table 2 an alphabetised list of these (CMGT), for example, cotransfer of galacto- disorders and the chromosomal location kinase and thymidine kinase. of the mutation in each case are pro- Ch = chromosomal change associated with vided. Both in the 'Disorder' field of table particular phenotype and not proved to repre- 1 and in table 2, the numbers 1, 2, or 3 in sent linkage (Fc), deletion (D), or virus effect parentheses after the name of the dis- (V), for example, loss of 13q14 band in some order indicate that its chromosomal cases of retinoblastoma. location was determined by mapping of the wildtype gene (1), by mapping of D = deletion or dosage mapping (concurrence the clinical phenotype (2), or by both of chromosomal deletion and phenotypic evid- strategies (3). ence of hemizygosity), trisomy mapping (pres- (J Med Genet 1993;30:1-26) ence of three alleles in the case of a highly polymorphic locus), or gene dosage effects (correlation of trisomic state of part or all of a The fields in the listing by chromosome (table chromosome with 50% more gene product). 1) are as follows: Includes 'loss of heterozygosity' (loss of alleles) in malignancies. Examples: acid phos- Location - that is, chromosomal site phatase- 1 to chromosome 2; glutathione Center for Medical = = Genetics, The Johns (p short arm; q long arm; numbers = band; reductase to chromosome 8. Includes DNA Hopkins University ter = end). dosage, for example, fibrinogen loci to 4q2. School of Medicine, Blalock Building, Symbol - The symbol approved by the Dosage mapping also includes coamplification Room 1007, 600 N Nomenclature Committee of the Human Gene in tumour cells. Wolfe Street, Mapping Workshops and their successor orga- Baltimore, MD EM= exclusion mapping, that is, narrowing 21287-4922, USA. nisation is given first; alternative symbols are the possible location of loci by exclusion of V A McKinsick included. parts of the map by deletion mapping, extended J S Amberger Status - C = confirmed; P = provisional; to include negative lod scores from families Correspondence to L= 'in limbo' (that is, tentative or inconsis- with marker chromosomes and negative lod Dr Amberger. tent). The 'in limbo' entries are not listed in scores with other assigned loci, for example, Received 12 October 1992. fig 1. support for assignment of MNSs to 4q. 2 McKusick, Amberger F = linkage study in families, for example, X/A = X-autosome translocation in female linkage of ABO blood group and nail-patella with X linked recessive disorder, for example, syndrome. (When a chromosomal heteromor- assignment of Duchenne muscular dystrophy phism or rearrangement is one trait, Fc is used, to Xp2l. for example, Duffy blood group locus on chro- Disorder - Allelic disorders are separated by mosome 1. When one or both of the linked loci semicolons. Brackets [ ] indicate a 'non- are identified by a DNA polymorphism, Fd is disease', that is, a variation with no definite used, for example, Huntington's disease on adverse consequences. Braces { ' indicate spe- chromosome 4. F = L in the HGM work- cific susceptibility or resistance with mono- shops.) genic basis. (1) = wildtype gene mapped. H = based on presumed homology, for (2) = disease phenotype mapped. (3) = both example, proposed assignment of TF to 3q. wildtype gene and disease phenotype mapped. Mainly heuristic or confirmatory. Mouse - Mouse chromosome carrying homo- HS = DNA/cDNA molecular hybridisation in logous gene. solution ('Cot analysis'). References for the mapping information and L = lyonisation, for example, OTC to X chro- additional information about the loci and dis- mosome. (L = symbol for family linkage study orders are provided in Mendelian Inheritance in the HGM workshops.) in Man, 10th ed (McKusick, 1992) and OMIMT (Online Mendelian Inheritance in LD = linkage disequilibrium, for example, Man). To obtain information on accessing beta and delta globin genes. OMIM, contact: M = Microcell mediated gene transfer (MMGT), In the United States: GDB/OMIM User for example, a collagen gene (COLlAl) to Support, Welch Medical Library, 1830 E chromosome 17. Monument Street, 3rd Floor, Baltimore, MD OT = ovarian teratoma (centromere mapping), 21205, USA (Telephone: 410-955-7058, Fax: for example, PGM3 and centromere of chro- 410-955-0054, e-mail: help(a welch.jhu.edu). mosome 6. In the United Kingdom: Christine Bates, Human Gene Mapping Program Resource Pcm = PCR of microdissected chromosome Centre, CRC, Watford Road, Harrow, Middx segments (see REI). HAl 3UJ, UK (Telephone: 44-81-869-3446, Psh = PCR of somatic cell hybrid DNA. Fax: 44-81-869-3807, e-mail: cbates(@uk.ac.crc). In Germany: Otto Ritter, German Cancer R = radiation hybrids, that is, irradiation of Research Centre (DKFZ), Molecular Bio- cells followed by 'rescue' through fusion with physics Group, Im Neuenheimer Feld 280, non-irradiated (non-human) cells (Goss-Har- D-6900 Heidelberg 1, FRG (Telephone: ris method of radiation-induced gene segrega- 49-6221-42-2372, Fax: 49-6221-40-1271, tion), for example, order of genes on Xq. e-mail: dok261 (a cvxl 2.dkfz-heidelberg.de). RE= restriction endonuclease techniques, for In Australia: Alex Reisner, ANGIS, Electri- example, fine structure map of the beta globin cal Engineering Building, J03, University of cluster (HBBC) on I lp; physical linkage of 3 Sydney, Sydney, NSW 2006, Australia, (Tele- fibrinogen genes (on 4q). phone: 61-2-692-294, Fax 61-2-692-3847, REa = combined with somatic cell hybridis- e-mail: reisner([email protected]). ation, for example, NAG (HBBC) to lip. REb = combined with chromosome sorting, for example, insulin to 1 lp. Includes Lebo's Discussion adaptation (dual laser chromosome sorting In these listings, 738 disorders in total are and spot blot DNA analysis), for example, indicated as assigned to specific chromosomes MGP to 1 q. (For this method, using flow and, in most instances, to specific regions of sorted chromosomes, W was the symbol those chromosomes. (More than 50 other dis- adopted by the HGM workshops.) orders are known to be caused by mutations in REc = hybridisation of cDNA to genomic genes on the X chromosome but their regional fragment (by YAC, PFGE, microdissection, location is not known and therefore they have etc), for example, A-11 on Xq. not been included here.) The 738 disorders are REl = isolation of gene from chromosome distributed over 625 loci; many loci have more specific genomic library (see Pcm). than one allelic mutation producing distinct REn = neighbour analysis in restriction phenotypes. for in field Some of the disorders (labelled with the fragments, example, pulsed gel number 1) have been mapped to specific sites electrophoresis (PFGE). by virtue of mapping of the wildtype gene; S = 'segregation' (cosegregation) of human cel- many forms of chronic non-spherocytic hae- lular traits and human chromosomes (or seg- molytic anaemia such as those due to pyruvate ments of chromosomes) in particular clones kinase deficiency, triosephosphate isomerase from interspecies somatic cell hybrids, for ex- deficiency, and bisphosphoglycerate mutase ample, thymidine kinase to chromosome 17. deficiency are examples. When with restriction enzyme, REa; with Other disorders (labelled with the number hybridisation in solution, HS. 2) are mapped only on the basis of the clinical V = induction of microscopically evident chro- phenotype which is found to be linked to mosomal change by a virus, for example, ade- markers at a particular chromosomal site or novirus 12 changes on chromosomes 1 and 17. the phenotype is found in association with a The morbid anatomy of the human genome 3 chromosomal aberration. Huntington's disease neoplasia type II are possible examples. Close is an example of a disorder mapped by linkage linkage of mutant genes, each responsible for a to DNA markers. specific component, in general is rejected as Yet other disorders (labelled with the the cause of genetic syndromes, in favour of number 3) have been mapped by both pleiotropism. The bona fide nature of some so approaches. The form of elliptocytosis due to a called contiguous gene syndromes is unques- defect in the gene encoding protein 4.1 is an tionable, however.
Load more

Recommended publications
  • Leading Article the Molecular and Genetic Base of Congenital Transport
    Gut 2000;46:585–587 585 Gut: first published as 10.1136/gut.46.5.585 on 1 May 2000. Downloaded from Leading article The molecular and genetic base of congenital transport defects In the past 10 years, several monogenetic abnormalities Given the size of SGLT1 mRNA (2.3 kb), the gene is large, have been identified in families with congenital intestinal with 15 exons, and the introns range between 3 and 2.2 kb. transport defects. Wright and colleagues12 described the A single base change was identified in the entire coding first, which concerns congenital glucose and galactose region of one child, a finding that was confirmed in the malabsorption. Subsequently, altered genes were identified other aZicted sister. This was a homozygous guanine to in partial or total loss of nutrient absorption, including adenine base change at position 92. The patient’s parents cystinuria, lysinuric protein intolerance, Menkes’ disease were heterozygotes for this mutation. In addition, it was (copper malabsorption), bile salt malabsorption, certain found that the 92 mutation was associated with inhibition forms of lipid malabsorption, and congenital chloride diar- of sugar transport by the protein. Since the first familial rhoea. Altered genes may also result in decreased secretion study, genomic DNA has been screened in 31 symptomatic (for chloride in cystic fibrosis) or increased absorption (for GGM patients in 27 kindred from diVerent parts of the sodium in Liddle’s syndrome or copper in Wilson’s world. In all 33 cases the mutation produced truncated or disease)—for general review see Scriver and colleagues,3 mutant proteins.
    [Show full text]
  • Open Full Page
    CCR PEDIATRIC ONCOLOGY SERIES CCR Pediatric Oncology Series Recommendations for Childhood Cancer Screening and Surveillance in DNA Repair Disorders Michael F. Walsh1, Vivian Y. Chang2, Wendy K. Kohlmann3, Hamish S. Scott4, Christopher Cunniff5, Franck Bourdeaut6, Jan J. Molenaar7, Christopher C. Porter8, John T. Sandlund9, Sharon E. Plon10, Lisa L. Wang10, and Sharon A. Savage11 Abstract DNA repair syndromes are heterogeneous disorders caused by around the world to discuss and develop cancer surveillance pathogenic variants in genes encoding proteins key in DNA guidelines for children with cancer-prone disorders. Herein, replication and/or the cellular response to DNA damage. The we focus on the more common of the rare DNA repair dis- majority of these syndromes are inherited in an autosomal- orders: ataxia telangiectasia, Bloom syndrome, Fanconi ane- recessive manner, but autosomal-dominant and X-linked reces- mia, dyskeratosis congenita, Nijmegen breakage syndrome, sive disorders also exist. The clinical features of patients with DNA Rothmund–Thomson syndrome, and Xeroderma pigmento- repair syndromes are highly varied and dependent on the under- sum. Dedicated syndrome registries and a combination of lying genetic cause. Notably, all patients have elevated risks of basic science and clinical research have led to important in- syndrome-associated cancers, and many of these cancers present sights into the underlying biology of these disorders. Given the in childhood. Although it is clear that the risk of cancer is rarity of these disorders, it is recommended that centralized increased, there are limited data defining the true incidence of centers of excellence be involved directly or through consulta- cancer and almost no evidence-based approaches to cancer tion in caring for patients with heritable DNA repair syn- surveillance in patients with DNA repair disorders.
    [Show full text]
  • 1 Accepted Preprint First Posted on 4 July 2018 As Manuscript EJE-18
    Page 1 of 26 Accepted Preprint first posted on 4 July 2018 as Manuscript EJE-18-0256 Title page Title: Approaches to molecular genetic diagnosis in the management of differences/disorders of sex development (DSD): position paper of EU COST Action BM 1303 "DSDnet" Authors: L. Audí 1, S.F. Ahmed 2, N. Krone 3, M. Cools 4, K. McElreavey 5, P.M. Holterhus 6, A. Greenfield 7, A. Bashamboo 5, O. Hiort 8, S.A. Wudy 9, R. McGowan 2,10, on behalf of the EU COST Action 1 Growth and Development Research Unit, Vall d’Hebron Research Institute (VHIR), Center for Biomedical Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Barcelona, 08035, Spain 2 Developmental Endocrinology Research Group, University of Glasgow, Glasgow, UK 3 Academic Unit of Child Health, Department of Oncology and Metabolism, University of Sheffield, Sheffield Children's Hospital, Western Bank, Sheffield S10 2TH, United Kingdom 4 Department of Paediatric Endocrinology, Ghent University Hospital, Paediatrics and Internal Medicine Research Unit, Ghent University, 9000 Ghent, Belgium 5 Human Developmental Genetics, Institut Pasteur, Paris, France 6 Division of Pediatric Endocrinology and Diabetes, University Hospital of Schleswig-Holstein and Christian Albrechts University, Kiel, Germany 7 Mammalian Genetics Unit, Medical Research Council, Harwell Institute, Oxfordshire, UK 1 Copyright © 2018 European Society of Endocrinology. Page 2 of 26 8 Division of Paediatric Endocrinology and Diabetes. Department of Paediatric and Adolescent Medicine, University of Lübeck, Lübeck, Germany 9 Steroid Research & Mass Spectrometry Unit, Laboratory for Translational Hormone Analytics, Division of Pediatric Endocrinology and Diabetology, Center of Child and Adolescent Medicine, Justus-Liebig-University, Giessen, Germany 10 Department of Clinical Genetics, Laboratories Building, Queen Elizabeth University Hospital, Glasgow, UK Corresponding author: Laura Audí Vall d’Hebron Research Institute (VHIR)- P.
    [Show full text]
  • EXTENDED CARRIER SCREENING Peace of Mind for Planned Pregnancies
    Focusing on Personalised Medicine EXTENDED CARRIER SCREENING Peace of Mind for Planned Pregnancies Extended carrier screening is an important tool for prospective parents to help them determine their risk of having a child affected with a heritable disease. In many cases, parents aren’t aware they are carriers and have no family history due to the rarity of some diseases in the general population. What is covered by the screening? Genomics For Life offers a comprehensive Extended Carrier Screening test, providing prospective parents with the information they require when planning their pregnancy. Extended Carrier Screening has been shown to detect carriers who would not have been considered candidates for traditional risk- based screening. With a simple mouth swab collection, we are able to test for over 419 genes associated with inherited diseases, including Fragile X Syndrome, Cystic Fibrosis and Spinal Muscular Atrophy. The assay has been developed in conjunction with clinical molecular geneticists, and includes genes listed in the NIH Genetic Test Registry. For a list of genes and disorders covered, please see the reverse of this brochure. If your gene of interest is not covered on our Extended Carrier Screening panel, please contact our friendly team to assist you in finding a gene test panel that suits your needs. Why have Extended Carrier Screening? Extended Carrier Screening prior to pregnancy enables couples to learn about their reproductive risk and consider a complete range of reproductive options, including whether or not to become pregnant, whether to use advanced reproductive technologies, such as preimplantation genetic diagnosis, or to use donor gametes.
    [Show full text]
  • Location Analysis of Estrogen Receptor Target Promoters Reveals That
    Location analysis of estrogen receptor ␣ target promoters reveals that FOXA1 defines a domain of the estrogen response Jose´ e Laganie` re*†, Genevie` ve Deblois*, Ce´ line Lefebvre*, Alain R. Bataille‡, Franc¸ois Robert‡, and Vincent Gigue` re*†§ *Molecular Oncology Group, Departments of Medicine and Oncology, McGill University Health Centre, Montreal, QC, Canada H3A 1A1; †Department of Biochemistry, McGill University, Montreal, QC, Canada H3G 1Y6; and ‡Laboratory of Chromatin and Genomic Expression, Institut de Recherches Cliniques de Montre´al, Montreal, QC, Canada H2W 1R7 Communicated by Ronald M. Evans, The Salk Institute for Biological Studies, La Jolla, CA, July 1, 2005 (received for review June 3, 2005) Nuclear receptors can activate diverse biological pathways within general absence of large scale functional data linking these putative a target cell in response to their cognate ligands, but how this binding sites with gene expression in specific cell types. compartmentalization is achieved at the level of gene regulation is Recently, chromatin immunoprecipitation (ChIP) has been used poorly understood. We used a genome-wide analysis of promoter in combination with promoter or genomic DNA microarrays to occupancy by the estrogen receptor ␣ (ER␣) in MCF-7 cells to identify loci recognized by transcription factors in a genome-wide investigate the molecular mechanisms underlying the action of manner in mammalian cells (20–24). This technology, termed 17␤-estradiol (E2) in controlling the growth of breast cancer cells. ChIP-on-chip or location analysis, can therefore be used to deter- We identified 153 promoters bound by ER␣ in the presence of E2. mine the global gene expression program that characterize the Motif-finding algorithms demonstrated that the estrogen re- action of a nuclear receptor in response to its natural ligand.
    [Show full text]
  • Inherited Metabolic Disorders)
    1 โรคพันธุกรรมเมตาบอลิก (inherited metabolic disorders) บทนํา โรคพันธุกรรมเมตาบอลิคนั้น มีผู้ประเมินไว้ว่ามีหลายร้อยโรคด้วยกัน และเป็นที่ยอมรับว่า อุบัติการของโรคกลุ่มนี้มักจะน้อยกว่าความเป็นจริง เนื่องจากการวินิจฉัยโรคทําได้ด้วยความ ยากลําบาก แพทย์ทั่วไปมักรู้จักค่อนข้างน้อย หรือให้การวินิจฉัยไม่ถูกต้อง ด้วยเหตุผลหลาย ประการ 1). การวินิจฉัยทําได้ค่อนข้างยาก เนื่องจากแต่ละโรคพบได้น้อยคือ จัดเป็น rare disease ทําให้แพทย์ไม่ค่อยนึกถึงเมื่อพบผู้ป่วย จนอาการค่อนข้างมาก หรือเมื่อได้แยกโรคที่พบได้บ่อย ออกไปแล้ว 2). การตรวจทางห้องปฎิบัติการโดยเฉพาะการตรวจเลือดและปัสสาวะเบื้องต้น มักไม่ ค่อยบอกโรคชัดเจน ยกเว้นส่งตรวจพิเศษบางอย่างเช่นการวิเคราะห์ plasma amino acid หรือ urine organic acid 3). ในทารกแรกเกิดซึ่งมีโอกาสพบโรคกลุ่มนี้ได้บ่อย มักจะมีการตอบสนองต่อ severe overwhelming illness อย่างมีขีดจํากัด หรือแสดงอาการอย่าง nonspecific เช่น poor feeding,lethargy เป็นต้น 4).กุมารแพทย์คิดถึงโรคกลุ่มนี้ในบางภาวะเท่านั้นเช่นภาวะปัญญาอ่อน หรือชักที่คุมได้ยากและมองข้ามอาการแสดงบางอย่างที่อาจเป็นเงื่อนงําสําคัญในการวินิจฉัยโรค โรคพันธุกรรมเมตาบอลิก ที่เรียกว่า inherited metabolic disorders หรือ inborn errors of metabolism (IBEM) เป็นโรคพันธุกรรมกลุ่มหนึ่งที่เกิดจากความผิดปกติของยีนเดี่ยว ที่มีความ ผิดปกติของการเรียงลําดับของเบสหรือสายDNA ก่อให้เกิดความผิดปกติของ enzymes, receptors, transport proteins, structural proteins, หรือส่วนประกอบอื่นของเซลล์แล้วส่งผลให้ เกิดความผิดปกติของขบวนการย่อยสลาย (catabolism) หรือขบวนการสังเคราะห์ (anabolism) สารอาหาร การเปลี่ยนแปลงที่ระดับ DNA ของโรคกลุ่มนี้อาจเกิดจากการกลายพันธุ์ของยีนที่สร้าง enzyme หรือยีนที่สร้างสารควบคุมหรือส่งเสริมการทํางานของ
    [Show full text]
  • What I Tell My Patients About Cystinuria
    BRITISH JOURNAL OF RENAL MEDICINE 2016; Vol 21 No 1 Patient information John A Sayer MB ChB FRCP PhD Consultant What I tell my patients Nephrologist1,2 Charles Tomson MA BM BCh FRCP DM Consultant Nephrologist2 about cystinuria 1 Institute of Genetic Medicine, Newcastle Cystinuria is an inherited condition that causes kidney stones in children and adults. University 2 Renal Services, Newcastle upon Tyne John A Sayer and Charles Tomson describe the effects of this condition and how to Hospitals NHS Foundation Trust, manage it successfully. Freeman Hospital, Newcastle upon Tyne Cystine is an amino acid found in high- Box 1. You say stones… I say calculi protein foods such as meat, eggs and dairy. High concentrations of cystine, particularly ‘Kidney stone’ and ‘renal calculus’ means the same thing – a solid piece of material that forms in the in acidic urine, result in crystallisation of kidneys. The word ‘calculus’ is derived from Latin, cystine, leading to the formation of kidney literally meaning ‘small pebble’, as used on an stones (see Box 1). These cystine stones are a abacus; the plural of calculus is calculi. ‘Nephrolith’ rare form of kidney stone, accounting for is another name for a kidney stone around 6% of kidney stones in children and around 1% of those in adults.1 Cystinuria is inherited in different ways and this can Cystinuria is estimated to affect 1 in 7,000 people.2 be confusing. Most patients have to inherit two faulty Despite the condition being present from birth, most copies of the gene involved (one inherited from their people affected will get their first stone in their mother and one from their father) to be affected by twenties, although a quarter of patients present in the condition.
    [Show full text]
  • Ebf Factors and Myod Cooperate to Regulate Muscle Relaxation Via Atp2a1
    ARTICLE Received 12 Feb 2014 | Accepted 2 Apr 2014 | Published 2 May 2014 DOI: 10.1038/ncomms4793 Ebf factors and MyoD cooperate to regulate muscle relaxation via Atp2a1 Saihong Jin1, Jeehee Kim1, Torsten Willert1, Tanja Klein-Rodewald2, Mario Garcia-Dominguez3,4, Matias Mosqueira5, Rainer Fink5, Irene Esposito2,6, Lorenz C. Hofbauer7, Patrick Charnay3 & Matthias Kieslinger1 Myogenic regulatory factors such as MyoD and Myf5 lie at the core of vertebrate muscle differentiation. However, E-boxes, the cognate binding sites for these transcription factors, are not restricted to the promoters/enhancers of muscle cell-specific genes. Thus, the specificity in myogenic transcription is poorly defined. Here we describe the transcription factor Ebf3 as a new determinant of muscle cell-specific transcription. In the absence of Ebf3 the lung does not unfold at birth, resulting in respiratory failure and perinatal death. This is due to a hypercontractile diaphragm with impaired Ca2 þ efflux-related muscle functions. Expression of the Ca2 þ pump Serca1 (Atp2a1) is downregulated in the absence of Ebf3, and its transgenic expression rescues this phenotype. Ebf3 binds directly to the promoter of Atp2a1 and synergises with MyoD in the induction of Atp2a1. In skeletal muscle, the homologous family member Ebf1 is strongly expressed and together with MyoD induces Atp2a1. Thus, Ebf3 is a new regulator of terminal muscle differentiation in the diaphragm, and Ebf factors cooperate with MyoD in the induction of muscle-specific genes. 1 Institute of Clinical Molecular Biology and Tumor Genetics, Helmholtz Zentrum Mu¨nchen, National Research Center for Environmental Health, Marchioninistrasse 25, 81377 Munich, Germany. 2 Institute of Pathology, Helmholtz Zentrum Mu¨nchen, National Research Center for Environmental Health, Ingolsta¨dter Landstr.
    [Show full text]
  • Blueprint Genetics Craniosynostosis Panel
    Craniosynostosis Panel Test code: MA2901 Is a 38 gene panel that includes assessment of non-coding variants. Is ideal for patients with craniosynostosis. About Craniosynostosis Craniosynostosis is defined as the premature fusion of one or more cranial sutures leading to secondary distortion of skull shape. It may result from a primary defect of ossification (primary craniosynostosis) or, more commonly, from a failure of brain growth (secondary craniosynostosis). Premature closure of the sutures (fibrous joints) causes the pressure inside of the head to increase and the skull or facial bones to change from a normal, symmetrical appearance resulting in skull deformities with a variable presentation. Craniosynostosis may occur in an isolated setting or as part of a syndrome with a variety of inheritance patterns and reccurrence risks. Craniosynostosis occurs in 1/2,200 live births. Availability 4 weeks Gene Set Description Genes in the Craniosynostosis Panel and their clinical significance Gene Associated phenotypes Inheritance ClinVar HGMD ALPL Odontohypophosphatasia, Hypophosphatasia perinatal lethal, AD/AR 78 291 infantile, juvenile and adult forms ALX3 Frontonasal dysplasia type 1 AR 8 8 ALX4 Frontonasal dysplasia type 2, Parietal foramina AD/AR 15 24 BMP4 Microphthalmia, syndromic, Orofacial cleft AD 8 39 CDC45 Meier-Gorlin syndrome 7 AR 10 19 EDNRB Hirschsprung disease, ABCD syndrome, Waardenburg syndrome AD/AR 12 66 EFNB1 Craniofrontonasal dysplasia XL 28 116 ERF Craniosynostosis 4 AD 17 16 ESCO2 SC phocomelia syndrome, Roberts syndrome
    [Show full text]
  • MECHANISMS in ENDOCRINOLOGY: Novel Genetic Causes of Short Stature
    J M Wit and others Genetics of short stature 174:4 R145–R173 Review MECHANISMS IN ENDOCRINOLOGY Novel genetic causes of short stature 1 1 2 2 Jan M Wit , Wilma Oostdijk , Monique Losekoot , Hermine A van Duyvenvoorde , Correspondence Claudia A L Ruivenkamp2 and Sarina G Kant2 should be addressed to J M Wit Departments of 1Paediatrics and 2Clinical Genetics, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, Email The Netherlands [email protected] Abstract The fast technological development, particularly single nucleotide polymorphism array, array-comparative genomic hybridization, and whole exome sequencing, has led to the discovery of many novel genetic causes of growth failure. In this review we discuss a selection of these, according to a diagnostic classification centred on the epiphyseal growth plate. We successively discuss disorders in hormone signalling, paracrine factors, matrix molecules, intracellular pathways, and fundamental cellular processes, followed by chromosomal aberrations including copy number variants (CNVs) and imprinting disorders associated with short stature. Many novel causes of GH deficiency (GHD) as part of combined pituitary hormone deficiency have been uncovered. The most frequent genetic causes of isolated GHD are GH1 and GHRHR defects, but several novel causes have recently been found, such as GHSR, RNPC3, and IFT172 mutations. Besides well-defined causes of GH insensitivity (GHR, STAT5B, IGFALS, IGF1 defects), disorders of NFkB signalling, STAT3 and IGF2 have recently been discovered. Heterozygous IGF1R defects are a relatively frequent cause of prenatal and postnatal growth retardation. TRHA mutations cause a syndromic form of short stature with elevated T3/T4 ratio. Disorders of signalling of various paracrine factors (FGFs, BMPs, WNTs, PTHrP/IHH, and CNP/NPR2) or genetic defects affecting cartilage extracellular matrix usually cause disproportionate short stature.
    [Show full text]
  • A Novel De Novo 20Q13.32&Ndash;Q13.33
    Journal of Human Genetics (2015) 60, 313–317 & 2015 The Japan Society of Human Genetics All rights reserved 1434-5161/15 www.nature.com/jhg ORIGINAL ARTICLE Anovelde novo 20q13.32–q13.33 deletion in a 2-year-old child with poor growth, feeding difficulties and low bone mass Meena Balasubramanian1, Edward Atack2, Kath Smith2 and Michael James Parker1 Interstitial deletions of the long arm of chromosome 20 are rarely reported in the literature. We report a 2-year-old child with a 2.6 Mb deletion of 20q13.32–q13.33, detected by microarray-based comparative genomic hybridization, who presented with poor growth, feeding difficulties, abnormal subcutaneous fat distribution with the lack of adipose tissue on clinical examination, facial dysmorphism and low bone mass. This report adds to rare publications describing constitutional aberrations of chromosome 20q, and adds further evidence to the fact that deletion of the GNAS complex may not always be associated with an Albright’s hereditary osteodystrophy phenotype as described previously. Journal of Human Genetics (2015) 60, 313–317; doi:10.1038/jhg.2015.22; published online 12 March 2015 INTRODUCTION resuscitation immediately after birth and Apgar scores were 9 and 9 at 1 and Reports of isolated subtelomeric deletions of the long arm of 10 min, respectively, of age. Birth parameters were: weight ~ 1.56 kg (0.4th–2nd chromosome 20 are rare, but a few cases have been reported in the centile), length ~ 40 cm (o0.4th centile) and head circumference ~ 28.2 cm o fi literature over the past 30 years.1–13 Traylor et al.12 provided an ( 0.4th centile).
    [Show full text]
  • Mitoxplorer, a Visual Data Mining Platform To
    mitoXplorer, a visual data mining platform to systematically analyze and visualize mitochondrial expression dynamics and mutations Annie Yim, Prasanna Koti, Adrien Bonnard, Fabio Marchiano, Milena Dürrbaum, Cecilia Garcia-Perez, José Villaveces, Salma Gamal, Giovanni Cardone, Fabiana Perocchi, et al. To cite this version: Annie Yim, Prasanna Koti, Adrien Bonnard, Fabio Marchiano, Milena Dürrbaum, et al.. mitoXplorer, a visual data mining platform to systematically analyze and visualize mitochondrial expression dy- namics and mutations. Nucleic Acids Research, Oxford University Press, 2020, 10.1093/nar/gkz1128. hal-02394433 HAL Id: hal-02394433 https://hal-amu.archives-ouvertes.fr/hal-02394433 Submitted on 4 Dec 2019 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Distributed under a Creative Commons Attribution| 4.0 International License Nucleic Acids Research, 2019 1 doi: 10.1093/nar/gkz1128 Downloaded from https://academic.oup.com/nar/advance-article-abstract/doi/10.1093/nar/gkz1128/5651332 by Bibliothèque de l'université la Méditerranée user on 04 December 2019 mitoXplorer, a visual data mining platform to systematically analyze and visualize mitochondrial expression dynamics and mutations Annie Yim1,†, Prasanna Koti1,†, Adrien Bonnard2, Fabio Marchiano3, Milena Durrbaum¨ 1, Cecilia Garcia-Perez4, Jose Villaveces1, Salma Gamal1, Giovanni Cardone1, Fabiana Perocchi4, Zuzana Storchova1,5 and Bianca H.
    [Show full text]